Navigation Links
Kosan's Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
Date:12/17/2007

safety, efficacy, regulatory status, commercialization and other characteristics of tanespimycin; and Kosan's development plans with respect to tanespimycin. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. There are a number of important factors that could cause the results of Kosan to differ materially from those indicated by these forward-looking statements, including, among others, risks and uncertainties related to the development of tanespimycin, including the risk that studies may not demonstrate safety and efficacy sufficient to initiate clinical trials, continue clinical development, obtain the requisite regulatory approvals or to result in a marketable product; Kosan's dependence upon the formation and sustainability of multiple partnering arrangements and license agreements with third parties, including with respect to its Hsp90 inhibitor and epothilone programs; Kosan's need for additional financing; Kosan's ability to obtain valid and enforceable patents covering its product candidates; Kosan's dependence on its collaboration with Pfizer for development of its motilin agonist product candidate; and other risks detailed from time to time in the Kosan's SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2007 and other periodic filings with the SEC. Kosan does not undertake any obligation to update forward-looking statements.

Velcade(R) (bortezomib) is a registered trademark of Millennium Pharmaceuticals, Inc.

Herceptin(R) (trastuzumab) is a registered trademark of Genentech, Inc.

Cremophor(R) is a registered trademark of BASF Corporation


'/>"/>
SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors
2. New Oral MEK Inhibitor, RDEA119, Shows Favorable Anti-Tumor Properties
3. 3 strikes, youre out? Refiling of Amendment to Change Constitution to Criminalize Stem Cell Cures Shows Trouble with Anti-Cures Cause
4. New Study Shows Promise for Hydrogen Sulfide in Reducing Heart-Attack Damage, Ikaria Announces
5. International Survey Shows People Over Forty Ignore Risk of Blindness
6. Aidas Rh-Apo2L Clinical Testing Shows Preliminary Efficacy in Helping to Treat Lung Cancer, Stomach Cancer, Lymphoma, Pancreatic Cancer & Kidney Cancer
7. Celator(R) Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio of Irinotecan and Cisplatin to Improve Anti-tumor Activity
8. Video shows buckyballs form by shrink wrapping
9. National Survey Shows Most Women Are Not Satisfied With Their Progesterone Treatment
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... The first part of the session on “Best ... Studies” will cover comprehensive clinical support in early phase ... R&D costs and declining industry success in getting products ... collected in early Phase I/IIa study data to make ... development. , Next, the presenters will examine steps to ...
(Date:7/24/2014)... DIEGO , July 24, 2014   ... announced today the appointment of Adam Simpson ... Cypher Genomics provides rapid and comprehensive annotation and ... and clinical reporting. "Cypher,s technology has ... improve healthcare by enhancing diagnostic accuracy, optimizing therapeutic ...
(Date:7/23/2014)... 24, 2014 Lyfebulb, the International Pemphigus ... and NASDAQ OMX First North Premier, ... announced a collaboration to increase awareness of unmet ... an event attended by more than sixty patients, ... a health and wellness company dedicated to serving ...
(Date:7/23/2014)... strides in saving China,s endangered national treasure, the giant ... panda reserves that have been established and three large ... remain in the wild. , Breeding programs in ... by improving genetic diversity, avoid inbreeding and ultimately, introduce ... high-profile programs doing so far? , In a new ...
Breaking Biology Technology:Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 2Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 3Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 2Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 3Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 4Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 5
... Nov. 3 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:,ONC, ... positive interim,results in its Phase I and Phase ... patients with advanced cancers.,The principal investigator for the ... Cancer Research and The Royal Marsden NHS Foundation ...
... Zentaris Inc.,(NASDAQ: AEZS ; TSX: AEZ), a ... today reported that it has entered the,second stage ... in endometrial,cancer with AEZS-108, a luteinizing hormone-releasing hormone ... the second stage of,patient recruitment was taken following ...
... Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: NTII ), ... payment of approximately $2.0 million from Merz,Pharmaceuticals ... the treatment of,moderate-to-severe Alzheimer,s disease. Under an ... payments on certain,sales of Memantine by Merz ...
Cached Biology Technology:Oncolytics Biotech Inc. Collaborators Present Positive Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting 2Oncolytics Biotech Inc. Collaborators Present Positive Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting 3Oncolytics Biotech Inc. Collaborators Present Positive Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting 4AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 2AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 3AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 4AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 5
(Date:7/24/2014)... The University of Texas Health Science Center at Houston ... help Harris County residents whose vision problems cannot be ... corrective lenses, many people with low vision can see ... low vision devices, such as telescopes, magnifiers and electronic ... is using the three-year, $164,645 SightFirst grant from the ...
(Date:7/24/2014)... (July 24, 2014) For years, researchers and patients ... nearly any cell type in the bodycould provide insight ... them. Yet progress has been hampered by the inability ... to their human counterparts, in part because human ESCs ... cells. , Now Thorold Theunissen, Benjamin Powell, and Haoyi ...
(Date:7/24/2014)... of fires covered central Africa in mid-July 2014, as ... red hotspots, which indicate areas of increased temperatures, are ... Democratic Republic of the Congo (northeast), and Zambia (southeast). ... and in some areas, especially in the Democratic Republic ... the south. , The fire season is an annual ...
Breaking Biology News(10 mins):UTHealth Dr. Bhavani Iyer awarded low vision grant 2Whitehead Institute researchers create 'naïve' pluripotent human embryonic stem cells 2
... researchers at The Johns Hopkins University School of Medicine reveal ... papers appear in the March issue of The Journal ... opening, many ion channels spontaneously close by inactivation, a process ... channels is important for a variety of biological processes, including ...
... Illinois study touts the benefits of soluble fiberfound in ... the inflammation associated with obesity-related diseases and strengthens the ... immune cellsthey go from being pro-inflammatory, angry cells to ... infection," said Gregory Freund, a professor in the U ...
... NEW ORLEANS, LA. Minerals Management Service (MMS) ... biologists have set sail to learn more about the ... Mexico. The first of the research cruise,s three legs ... is underway. The first and second legs of ...
Cached Biology News:An apple a day? Study shows soluble fiber boosts immune system 2An apple a day? Study shows soluble fiber boosts immune system 3MMS and NOAA scientists study prey of Gulf of Mexico sperm whales 2
Anti-human L-Ficolin, Clone GN4, Monoclonal Antibody...
14-3-3 tau Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Applications: Western blotting Stability: Room temperature, indefinitely ...
... to ARG. Vasopressin The antibody ... Cells are found in the paraventricular ... found throughout the hypothalmus in rat ... Immunogen: Arginine ...
Biology Products: